Aug 12, 2023 | Blog, CenExel, CenExel FCR, News, Press Releases
Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo effects within central nervous system and internal medicine clinical trials and developing...Jul 25, 2023 | Blog, CenExel, CenExel FCR, News, Press Releases
Tampa, Florida, July 26, 2023 /GlobeNewswire/ — CenExel FCR has been named the 2023 Tampa Bay Times People’s Choice, Best of the Best in Clinical Research. This remarkable achievement showcases CenExel FCR’s unwavering dedication to advancing medical...Jul 15, 2023 | Blog, CenExel, News, Press Releases
Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our new CEO effective July 17, 2023. Tom Wardle will transition to the role of Executive Chairman, CenExel Board of...May 17, 2023 | Blog, CenExel, CenExel FCR, News, Press Releases
Salt Lake City, May 18, 2023 /GlobeNewswire/ — CenExel announces the addition of Michele Baptista as the new Senior Director of Business Development. In this new capacity, Michele will be responsible for developing, selling, and supporting CenExel’s 18-site network...Apr 21, 2023 | Blog, News, Posters
CenExel is proud to highlight the poster we’re presenting at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2023, Miami, FL. ABSTRACT Introduction: Placebo and nocebo responses continue to hinder potential treatment effects...
Recent Comments